MADISON, Wis., & HOUSTON--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS) and The University of Texas MD Anderson Cancer Center today announced an agreement to jointly develop and commercialize blood-based screening and diagnostic tests for the early detection of lung cancer.
This unique collaboration seeks to build upon MD Anderson’s extensive research into predictive biomarkers for lung cancer and Exact Sciences’ successful development and commercialization of Cologuard®, the only FDA-approved, non-invasive stool-based DNA colon cancer screening test. The two groups plan to develop a groundbreaking new blood test that targets biomarkers associated with lung cancer.
Help employers find you! Check out all the jobs and post your resume.
This unique collaboration seeks to build upon MD Anderson’s extensive research into predictive biomarkers for lung cancer and Exact Sciences’ successful development and commercialization of Cologuard®, the only FDA-approved, non-invasive stool-based DNA colon cancer screening test. The two groups plan to develop a groundbreaking new blood test that targets biomarkers associated with lung cancer.
Help employers find you! Check out all the jobs and post your resume.
